Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Blinded Treatment Period (Weeks 0-24)	STARTED	Ixekizumab	520
Blinded Treatment Period (Weeks 0-24)	STARTED	Guselkumab	507
Blinded Treatment Period (Weeks 0-24)	Received at Least One Dose of Study Drug	Ixekizumab	519
Blinded Treatment Period (Weeks 0-24)	Received at Least One Dose of Study Drug	Guselkumab	506
Blinded Treatment Period (Weeks 0-24)	COMPLETED	Ixekizumab	465
Blinded Treatment Period (Weeks 0-24)	COMPLETED	Guselkumab	459
Blinded Treatment Period (Weeks 0-24)	NOT COMPLETED	Ixekizumab	55
Blinded Treatment Period (Weeks 0-24)	NOT COMPLETED	Guselkumab	48
Post-Treatment Follow Up (Weeks 25-36)	STARTED	Ixekizumab	465
Post-Treatment Follow Up (Weeks 25-36)	STARTED	Guselkumab	456
Post-Treatment Follow Up (Weeks 25-36)	COMPLETED	Ixekizumab	406
Post-Treatment Follow Up (Weeks 25-36)	COMPLETED	Guselkumab	399
Post-Treatment Follow Up (Weeks 25-36)	NOT COMPLETED	Ixekizumab	59
Post-Treatment Follow Up (Weeks 25-36)	NOT COMPLETED	Guselkumab	57

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03573323/flow